Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P16885
UPID:
PLCG2_HUMAN
Alternative names:
Phosphoinositide phospholipase C-gamma-2; Phospholipase C-IV; Phospholipase C-gamma-2
Alternative UPACC:
P16885; D3DUL3; Q3ZTS2; Q59H45; Q969T5
Background:
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2, also known as Phosphoinositide phospholipase C-gamma-2, plays a pivotal role in transmembrane signaling by generating diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). These second messenger molecules are crucial for various cellular processes.
Therapeutic significance:
This protein's involvement in Familial cold autoinflammatory syndrome 3 and Autoinflammation, antibody deficiency, and immune dysregulation highlights its potential as a target for therapeutic intervention. Understanding its role could lead to novel treatments for these immune disorders.